THE-630 phase 1 preliminary dose-escalation data anticipated in Q2 2023; additional data including dose levels projected preclinically to provide pan-variant KIT coverage planned for Q4 2023
Read more at prnewswire.comProvided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.